Kyowa Kirin International Plc

Specialty pharmaceutical company engaged in development and commercialisation of prescription medicines for treatment of unmet therapeutic needs.

At Kyowa Kirin International plc “Commitment to Life” is at our core. With over 500 people focused on this purpose we’ve become a highly success and rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of unmet therapeutic needs in major western markets.

Kyowa Kirin International plc is owned by Kyowa Hakko Kirin Co. , Ltd (KHK) of Japan. Founded in 1949, KHK has a successful track record in Japan and is now expanding globally. Our highly successful product portfolio, enviable pipeline and active Business Development group provides a wealth of products in the therapeutic areas of Oncology, CNS and Nephrology. With three key anti-body therapies in late stage development Kyowa Kirin is setting the scene for transformative growth.

As the Western Commercial centre we are headquartered in Scotland (south of Edinburgh) with commercial offices in London, across the EU and New Jersey, USA. KHK also has Development operations in Scotland and Princeton.

At Kyowa Kirin we believe it is our people who have made the real difference to our success. Working together, our employees excel in getting results quickly and flawlessly. Our passion and energy around our core purpose of “Commitment to Life” sets us apart.

With our solid past and exciting future Kyowa Kirin is looking for great people to join our team.